{"count": 3, "results": [{"_id": "34069550", "pmid": 34069550, "pmcid": "PMC8161333", "title": "A Phase Ib Clinical Trial of Metformin and Chloroquine in Patients with IDH1-Mutated Solid Tumors", "journal": "Cancers (Basel)", "authors": ["Khurshed M", "Molenaar RJ", "van Linde ME", "Mathôt RA", "Struys EA", "van Wezel T", "van Noorden CJF", "Klümpen HJ", "Bovée JVMG", "Wilmink JW"], "date": "2021-05-19T00:00:00Z", "doi": "10.3390/cancers13102474", "meta_date_publication": "2021 May 19", "meta_volume": "13", "meta_issue": "10", "meta_pages": "", "score": 50266.53, "text_hl": "However, sensitivity to @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ in @<m>DISEASE_Chondrosarcoma</m> @DISEASE_MESH:D002813 @@@chondrosarcoma@@@ cell lines was independent of the presence of an IDH1 mutation. ", "citations": {"NLM": "Khurshed M, Molenaar RJ, van Linde ME, Mathôt RA, Struys EA, van Wezel T, van Noorden CJF, Klümpen HJ, Bovée JVMG, Wilmink JW. A Phase Ib Clinical Trial of Metformin and Chloroquine in Patients with IDH1-Mutated Solid Tumors Cancers (Basel). 2021 May 19;13(10):. PMID: 34069550", "BibTeX": "@article{34069550, title={A Phase Ib Clinical Trial of Metformin and Chloroquine in Patients with IDH1-Mutated Solid Tumors}, author={Khurshed M and Molenaar RJ and van Linde ME and Mathôt RA and Struys EA and van Wezel T and van Noorden CJF and Klümpen HJ and Bovée JVMG and Wilmink JW}, journal={Cancers (Basel)}, volume={13}, number={10}}"}}, {"_id": "29576625", "pmid": 29576625, "pmcid": "PMC5931088", "title": "Targeting glutaminolysis in chondrosarcoma in context of the IDH1/2 mutation", "journal": "Br J Cancer", "authors": ["Peterse EFP", "Niessen B", "Addie RD", "de Jong Y", "Cleven AHG", "Kruisselbrink AB", "van den Akker BEWM", "Molenaar RJ", "Cleton-Jansen AM", "Bovée JVMG"], "date": "2018-04-01T00:00:00Z", "doi": "10.1038/s41416-018-0050-9", "meta_date_publication": "2018 Apr", "meta_volume": "118", "meta_issue": "8", "meta_pages": "1074-1083", "score": 50076.188, "text_hl": "...@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ is sufficiently transported into @<m>DISEASE_Chondrosarcoma</m> @DISEASE_MESH:D002813 @@@chondrosarcoma@@@ cells to completely inhibit mitochondrial respiration", "citations": {"NLM": "Peterse EFP, Niessen B, Addie RD, de Jong Y, Cleven AHG, Kruisselbrink AB, van den Akker BEWM, Molenaar RJ, Cleton-Jansen AM, Bovée JVMG. Targeting glutaminolysis in chondrosarcoma in context of the IDH1/2 mutation Br J Cancer. 2018 Apr;118(8):1074-1083. PMID: 29576625", "BibTeX": "@article{29576625, title={Targeting glutaminolysis in chondrosarcoma in context of the IDH1/2 mutation}, author={Peterse EFP and Niessen B and Addie RD and de Jong Y and Cleven AHG and Kruisselbrink AB and van den Akker BEWM and Molenaar RJ and Cleton-Jansen AM and Bovée JVMG}, journal={Br J Cancer}, volume={118}, number={8}, pages={1074-1083}}"}}, {"_id": "28601826", "pmid": 28601826, "pmcid": "PMC5541450", "title": "Study protocol of a phase IB/II clinical trial of metformin and chloroquine in patients with IDH1-mutated or IDH2-mutated solid tumours", "journal": "BMJ Open", "authors": ["Molenaar RJ", "Coelen RJS", "Khurshed M", "Roos E", "Caan MWA", "van Linde ME", "Kouwenhoven M", "Bramer JAM", "Bovée JVMG", "Mathôt RA", "Klümpen HJ", "van Laarhoven HWM", "van Noorden CJF", "Vandertop WP", "Gelderblom H", "van Gulik TM", "Wilmink JW"], "date": "2017-06-10T00:00:00Z", "doi": "10.1136/bmjopen-2016-014961", "meta_date_publication": "2017 Jun 10", "meta_volume": "7", "meta_issue": "6", "meta_pages": "e014961", "score": 50054.01, "text_hl": "Possible concerns may be related to the bioavailability of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@. We have observed high expression of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ transporters in @<m>DISEASE_Chondrosarcoma</m> @DISEASE_MESH:D002813 @@@chondrosarcoma@@@, @DISEASE_Glioma @DISEASE_MESH:D005910 @@@glioma@@@, and @DISEASE_Cholangiocarcinoma @DISEASE_MESH:D018281 @@@intrahepatic cholangiocarcinoma@@@ cell lines and primary tissue (OCT1-3; The @DISEASE_Neoplasms @DISEASE_MESH:D009369 @@@Cancer@@@ Cell Line Encylopedia and our own unpublished data). ", "citations": {"NLM": "Molenaar RJ, Coelen RJS, Khurshed M, Roos E, Caan MWA, van Linde ME, Kouwenhoven M, Bramer JAM, Bovée JVMG, Mathôt RA, Klümpen HJ, van Laarhoven HWM, van Noorden CJF, Vandertop WP, Gelderblom H, van Gulik TM, Wilmink JW. Study protocol of a phase IB/II clinical trial of metformin and chloroquine in patients with IDH1-mutated or IDH2-mutated solid tumours BMJ Open. 2017 Jun 10;7(6):e014961. PMID: 28601826", "BibTeX": "@article{28601826, title={Study protocol of a phase IB/II clinical trial of metformin and chloroquine in patients with IDH1-mutated or IDH2-mutated solid tumours}, author={Molenaar RJ and Coelen RJS and Khurshed M and Roos E and Caan MWA and van Linde ME and Kouwenhoven M and Bramer JAM and Bovée JVMG and Mathôt RA and Klümpen HJ and van Laarhoven HWM and van Noorden CJF and Vandertop WP and Gelderblom H and van Gulik TM and Wilmink JW}, journal={BMJ Open}, volume={7}, number={6}, pages={e014961}}"}}]}